JP2023500873A - 低減した粒度を有するウイルスワクチンを生成するための組成物および方法 - Google Patents

低減した粒度を有するウイルスワクチンを生成するための組成物および方法 Download PDF

Info

Publication number
JP2023500873A
JP2023500873A JP2022525700A JP2022525700A JP2023500873A JP 2023500873 A JP2023500873 A JP 2023500873A JP 2022525700 A JP2022525700 A JP 2022525700A JP 2022525700 A JP2022525700 A JP 2022525700A JP 2023500873 A JP2023500873 A JP 2023500873A
Authority
JP
Japan
Prior art keywords
virus particles
virus
polysorbate
particles
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500873A5 (https=
Inventor
クリストファー ダッド，
マシュー スミス，
デブラ リディアード，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seqirus UK Ltd
Original Assignee
Seqirus UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus UK Ltd filed Critical Seqirus UK Ltd
Publication of JP2023500873A publication Critical patent/JP2023500873A/ja
Publication of JP2023500873A5 publication Critical patent/JP2023500873A5/ja
Priority to JP2025052605A priority Critical patent/JP2025092571A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022525700A 2019-11-07 2020-11-06 低減した粒度を有するウイルスワクチンを生成するための組成物および方法 Pending JP2023500873A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025052605A JP2025092571A (ja) 2019-11-07 2025-03-26 低減した粒度を有するウイルスワクチンを生成するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931909P 2019-11-07 2019-11-07
US62/931,909 2019-11-07
PCT/IB2020/000961 WO2021090067A2 (en) 2019-11-07 2020-11-06 Compositions and methods for producing a viral vaccine with reduced particle size

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025052605A Division JP2025092571A (ja) 2019-11-07 2025-03-26 低減した粒度を有するウイルスワクチンを生成するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2023500873A true JP2023500873A (ja) 2023-01-11
JP2023500873A5 JP2023500873A5 (https=) 2023-11-02

Family

ID=74104121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525700A Pending JP2023500873A (ja) 2019-11-07 2020-11-06 低減した粒度を有するウイルスワクチンを生成するための組成物および方法
JP2025052605A Pending JP2025092571A (ja) 2019-11-07 2025-03-26 低減した粒度を有するウイルスワクチンを生成するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025052605A Pending JP2025092571A (ja) 2019-11-07 2025-03-26 低減した粒度を有するウイルスワクチンを生成するための組成物および方法

Country Status (11)

Country Link
US (1) US20230220356A1 (https=)
EP (1) EP4054630A2 (https=)
JP (2) JP2023500873A (https=)
KR (1) KR20220098370A (https=)
CN (1) CN114929270A (https=)
AU (1) AU2020380604A1 (https=)
BR (1) BR112022008711A2 (https=)
CL (2) CL2022001176A1 (https=)
IL (1) IL292699A (https=)
MX (1) MX2022005513A (https=)
WO (1) WO2021090067A2 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1121253A (ja) * 1997-04-09 1999-01-26 Duphar Internatl Res Bv インフルエンザワクチン
JP2011515387A (ja) * 2008-03-18 2011-05-19 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP2014524747A (ja) * 2011-07-20 2014-09-25 アボツト・バイオロジカルズ・ベー・ブイ ウイルス抗原およびワクチンの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
CA2438960A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
ES2525518T3 (es) * 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103370072B (zh) * 2010-12-15 2016-02-03 巴克斯特国际公司 使用改进的溶剂-清洁剂方法进行病毒灭活
CN102690334A (zh) * 2011-03-21 2012-09-26 王一丁 一种病毒类疫苗的纯化方法
WO2013173256A2 (en) * 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
WO2019045090A1 (ja) * 2017-09-04 2019-03-07 公益財団法人ヒューマンサイエンス振興財団 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EA202192398A1 (ru) * 2019-03-04 2021-11-23 Джэпэн Эз Репризентид Баи Директор Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизис Способ приготовления сплит-вакцины против гриппа на основе гемагглютинина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1121253A (ja) * 1997-04-09 1999-01-26 Duphar Internatl Res Bv インフルエンザワクチン
JP2011515387A (ja) * 2008-03-18 2011-05-19 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP2014524747A (ja) * 2011-07-20 2014-09-25 アボツト・バイオロジカルズ・ベー・ブイ ウイルス抗原およびワクチンの製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MED MICROBIOL IMMUNOL, vol. 203, JPN6024038362, 2014, pages 47 - 55, ISSN: 0005819904 *
PLOS ONE, vol. 7, JPN6024038361, 2012, pages 52135, ISSN: 0005819903 *
VACCINE, vol. 29, JPN6024038360, 2011, pages 2037 - 2043, ISSN: 0005819902 *

Also Published As

Publication number Publication date
WO2021090067A3 (en) 2021-06-10
EP4054630A2 (en) 2022-09-14
BR112022008711A2 (pt) 2022-07-19
US20230220356A1 (en) 2023-07-13
CL2022001176A1 (es) 2023-01-20
MX2022005513A (es) 2022-06-08
CN114929270A (zh) 2022-08-19
JP2025092571A (ja) 2025-06-19
IL292699A (en) 2022-07-01
KR20220098370A (ko) 2022-07-12
CL2025002531A1 (es) 2025-12-19
WO2021090067A2 (en) 2021-05-14
AU2020380604A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP6275641B2 (ja) ウイルス抗原およびワクチンの製造方法
Weigel et al. A flow-through chromatography process for influenza A and B virus purification
AU2012286098B2 (en) Process for producing viral antigen and vaccines
CN107567496B (zh) 有关病毒的无菌纯化方法
JP2017524360A (ja) 細胞培養体からのポリオウイルスの精製プロセス
US20120058145A1 (en) Method for producing virus from cell culture involving homogenization
AU2004249802B2 (en) Improvements in virus production
CN105473712B (zh) 在细胞培养物中大规模生产病毒
CN105612250A (zh) 经处理的滤器
JP2023500873A (ja) 低減した粒度を有するウイルスワクチンを生成するための組成物および方法
EP3234113B1 (en) A method for a large scale virus purification
Weigel Development of chromatography-based purification processes for cell culture-derived influenza virus particles
CN100398642C (zh) 病毒生产的改进
CN120192936A (zh) 一种高剂量流感病毒裂解疫苗原液的制备方法
JP2023500873A5 (https=)
JP2025167597A (ja) ウイルスクリアランス性能の決定方法
AU2007221746A1 (en) Improvements in virus production
WO2010079081A1 (en) Methods for recovering a virus or a viral antigen produced by cell culture
HK1194763A (en) Process for producing viral antigen and vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260318